Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.

ABSTRACT:

Background

The human genome displays extensive copy-number variation (CNV). Recent discoveries have shown that large segments of DNA, ranging in size from hundreds to thousands of nucleotides, are either deleted or duplicated. This CNV may encompass genes, leading to a change in phenotype, including drug response phenotypes. Gemcitabine and 1-beta-D-arabinofuranosylcytosine (AraC) are cytidine analogues used to treat a variety of cancers. Previous studies have shown that genetic variation may influence response to these drugs. In the present study, we set out to test the hypothesis that variation in copy number might contribute to variation in cytidine analogue response phenotypes.

Results

We used a cell-based model system consisting of 197 ethnically-defined lymphoblastoid

SUBMITTER: Kalari KR 

PROVIDER: S-EPMC2894803 | biostudies-literature | 2010 Jun

REPOSITORIES: biostudies-literature